Sanket Koul

Delhi AQI worsens after Diwali; pollution sparks political blame game

Delhi's AQI touched 372 on Monday after Diwali celebrations, triggering health concerns, questions over pollution monitoring and a political row over stubble burning in Punjab

Fortis Q2 net profit falls 2.5% on higher expenses, lower exceptional gain

Fortis Healthcare's Q2FY27 net profit declined to ₹320 crore as expenses rose, while revenue grew 17 per cent to ₹2,735 crore, driven by hospitals and diagnostics

Govt proposes immediate licence suspension for substandard drugmakers

The Health Ministry has proposed suspending manufacturing licences immediately after drugs fail critical quality tests, aiming to prevent unsafe medicines from remaining in circulation.

Stricter microbial contamination norms under Schedule M in offing

The Union Health Ministry has proposed tightening microbial contamination limits in Grade A clean areas to align India's pharmaceutical manufacturing standards with WHO guidelines

Manipal signs 30-year lease with Thakral for 500-bed Gurugram hospital

Manipal Health Enterprises will develop and operate a multi-specialty hospital on 3.5 acres in Gurugram under a 30-year lease, with the estimated investment pegged at ₹750 crore

Dr Lal PathLabs Q2 net profit rises 27.5% to ₹194 cr on volume growth

Dr Lal PathLabs reported a 19.6 per cent rise in Q2FY27 revenue to ₹874 crore as sample volumes grew 13.6 per cent and patient coverage increased 9 per cent

Centre plans to expand import clearance gateways for drugs, medical devices

The Health Ministry proposes adding seven inland container depots, an SEZ and Jewar airport to the approved list to ease imports of drugs, medical devices and cosmetics

Centre proposes mandatory qualified personnel for drug batch release

The proposed amendments seek to strengthen accountability in drug manufacturing by requiring qualified personnel for batch release and maintaining prescribed records

Pharma industry seeks clarity on CDSCO solvent order's export ambit

Pharma executives seek clarity on export applicability of CDSCO's batch-wise solvent clearance rules, warning that approval delays could disrupt supplies, particularly in rural markets

CDSCO mandates digital batchwise clearance for high-risk pharma solvents

Drug regulator CDSCO has mandated digital clearance for every batch of high-risk pharmaceutical solvents, prompting industry concerns over delays and potential supply disruptions

RPG Life Sciences eyes another acquisition with ₹500 crore capital pool

The drugmaker plans to deploy ₹500 crore for another acquisition within 12 months as it targets 25 per cent annual growth in its API business over the next five years

Govt mandates at least 1-year residual shelf life for imported drugs

The Health Ministry has replaced the 60 per cent residual shelf-life requirement with a fixed 12-month minimum for most imported drugs, aiming to ease imports and reduce wastage

Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses

Max Healthcare's Q2FY27 net profit declined 15.6 per cent to ₹414.45 crore as operating and tax expenses rose, even as revenue grew 16.8 per cent on higher patient demand.

India's pharma exports grow 4.9% to $16.14 bn in H1FY27 on Europe gains

India's pharmaceutical exports rose 4.9 per cent to $16.14 billion in H1FY27, driven by growth in Europe, ASEAN and Latin America, even as shipments to the US moderated.

India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report

India's pharma and healthcare sector recorded 87 deals worth $4.3 billion in Q3 2026, as private equity activity surged and public market fundraising gained momentum.

Centre cuts MRPs for trade-margin-capped cancer meds by up to 93%

Major innovator brands see no price reductions despite cuts of up to 93 per cent for some cancer medicines; patient groups say PAP exclusions and data gaps have diluted relief

CDSCO asks states, UTs to mandate raw material tests for drugmakers

The drug regulator has asked states and UTs to enforce raw material testing and vendor qualification by manufacturers, following concerns over contaminated cough syrups and drug safety.

Indian MBBS aspirants seek a cheaper cure for seat crunch in Central Asia

Central Asia gains appeal on fees as junior doctor status in Georgia faces scrutiny over eligibility

Cipla Q2 net profit falls 35% to ₹878 cr as US business weighs on sales

Cipla's consolidated revenue declined 2.4% to Rs 7,404 crore in Q2 FY27 as its North America and API businesses weakened, while India revenue grew 12% to Rs 3,516 crore

Cap on cancer drug margins may not lower patients' medical bills: Experts

Experts warn that the 30% trade-margin cap on 137 anti-cancer drugs may offer limited relief to patients as assistance programmes remain excluded from price calculations.